Evidence map›Paper›PMID 42927222›Full record

ArticleKidney international reports2026

Acute eGFR Changes With Finerenone Examined in a Prespecified Analysis of FINE-ONE.

David Z I Cherney, Tae Won Yi, Hiddo J L Heerspink, Linong Ji, Janet B McGill, Peter Rossing, Katherine R Tuttle, Jesper N Bech, Paolo Fiorina, Albert Power and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

David Z I CherneyDivision of Nephrology, University Health Network, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
Tae Won YiDivision of Nephrology, University Health Network, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
Hiddo J L HeerspinkThe George Institute for Global Health, University of New South Wales, Sydney, Australia.
Linong JiDepartment of Endocrinology and Metabolism, Peking University People's Hospital, Peking University Diabetes Center, Beijing, China.
Janet B McGillDivision of Endocrinology, Metabolism & Lipid Research, Washington University in St. Louis, School of Medicine, St. Louis, Missouri, USA.
Peter RossingSteno Diabetes Center Copenhagen, Herlev, Denmark.
Katherine R TuttleProvidence Medical Research Center, Providence Inland Northwest Health, Spokane, Washington, USA.
Jesper N BechDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Paolo FiorinaDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan and Università degli Studi di Milano, Milan, Italy.
Albert PowerPopulation Health Sciences, Bristol Medical School, University of Bristol, and Renal Unit, North Bristol NHS Trust, Bristol, UK.
Karoline SchousboeSteno Diabetes Center Odense, Odense University Hospital, Odense, Denmark.
Nicholas M SelbyCentre for Kidney Research and Innovation, Academic Unit for Translational Medical Sciences, Royal Derby Hospital Campus, University of Nottingham, Derby, UK.
Emanuela SetolaCardio-metabolic and Clinical Trials Unit, IRCCS Ospedale San Raffaele, Milan, Italy.
J David SmeijerDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
Robert LawatscheckCardiology and Nephrology Clinical Development, Bayer AG, Berlin, Germany.
Meike BrinkerCardiology and Nephrology Clinical Development, Bayer AG, Wuppertal, Germany.
Julie RussellBayer PLC, Reading, UK.
Patrick SchloemerClinical Statistics and Analytics, Bayer AG, Berlin, Germany.
Per-Henrik GroopDepartment of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
FINE-ONE Investigators23

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The nonsteroidal mineralocorticoid receptor antagonist finerenone reduces urine albumin-to-creatinine ratio (UACR) in people with type 1 diabetes (T1D) and chronic kidney disease (CKD). This prespecified analysis evaluated acute changes in estimated glomerular filtration rate (eGFR) with finerenone and their impact on safety. Methods: Adults with T1D and CKD ( Results: Mean acute eGFR decline at month 1 was greater with finerenone (-2.78 ml/min per 1.73 m Conclusion: In people with T1D and CKD, finerenone induced an acute eGFR dip that was well tolerated without unexpected safety signals.

Indexed as

chronic kidney diseaseeGFRfinerenoneglomerular filtration ratenonsteroidal mineralocorticoid receptor antagonisttype 1 diabetes

Identifiers

PMID42927222
PMCPMC13694952

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.